On Nov 14, major Wall Street analysts update their ratings for $Sangamo Therapeutics (SGMO.US)$, with price targets ranging from $3 to $10.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $9.
Wells Fargo analyst Yanan Zhu maintains with a hold rating, and adjusts the target price from $1 to $3.
TD Cowen analyst Ritu Baral maintains with a buy rating.
H.C. Wainwright analyst Patrick Trucchio maintains with a buy rating, and maintains the target price at $10.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following Sangamo's third-quarter report, there's an acknowledgment of the alignment with the FDA for an accelerated approval pathway. The discussion during the Q3 call primarily centered on the advancement of the Fabry program and the ongoing late-stage partnership talks. There is anticipation of favorable data by the third quarter of 2025 and potential FDA approval by 2026, with the expectation of a partnership deal being announced shortly.
The firm considers the establishment of a partnership regarding the Fabry program and the complete results from the pivotal study as crucial catalysts. It is believed that the potential rise in the stock's value will stem from the proof of concept of the company's proprietary ZFP transcription factor neurology programs.
Here are the latest investment ratings and price targets for $Sangamo Therapeutics (SGMO.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月14日，多家華爾街大行更新了$Sangamo Therapeutics (SGMO.US)$的評級，目標價介於3美元至10美元。
巴克萊銀行分析師Gena Wang維持買入評級，維持目標價9美元。
富國集團分析師Yanan Zhu維持持有評級，並將目標價從1美元上調至3美元。
TD Cowen分析師Ritu Baral維持買入評級。
H.C. Wainwright分析師Patrick Trucchio維持買入評級，維持目標價10美元。
此外，綜合報道，$Sangamo Therapeutics (SGMO.US)$近期主要分析師觀點如下：
根據Sangamo第三季度報告，在與FDA對齊進行加速批准途徑方面存在確認。在Q3看漲通話期間討論主要集中在Fabry項目的進展以及正在進行的後期夥伴關係談判。預計到2025年第三季度會出現有利數據，到2026年有可能獲得FDA批准，並期望很快宣佈夥伴關係交易。
公司認爲與Fabry項目有關的夥伴關係建立以及關鍵研究的完整結果是至關重要的催化劑。人們相信，公司專有的ZFP轉錄因子神經學項目的概念證明將使股價上漲。
以下爲今日4位分析師對$Sangamo Therapeutics (SGMO.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
